Loading...

NKTR NEKTAR THERAPEUTICS Disposals and divestitures 8-K Filing

NKTR

NKTR

NEKTAR THERAPEUTICS

(NKTR)

2023 8-K

Show Summary

Show Summary

Product Expansion

Reverse Stock Split

Reverse Stock Split

Financial Statements

Financial Results

Clinical Trial Agreement

Management Change

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results

Compliance with Minimum Bid...

Amendment to Purchase Agree...

Securities Purchase Agreement

Stock Repurchase

Earnings Reports

Financial Results Announcement

Financial Results Announcement

Disclosure and Other Events

Management Change

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Agreement

Restructuring Plan and CFO ...

External Links:

Nektar Therapeutics regains full rights to rezpegaldesleukin, a T-cell therapy, after termination of agreement with Eli Lilly.

AI Assistant

NEKTAR THERAPEUTICS

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.